Author: "de Lange, Marit" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"de Lange, Marit"' showing total 110 results

Start Over Author "de Lange, Marit"

110 results on '"de Lange, Marit"'

1. Pediatric acute flaccid myelitis: Evaluation of diagnostic criteria and differentiation from other causes of acute flaccid paralysis

Author: Helfferich, Jelte, Neuteboom, Rinze F., de Lange, Marit M.A., Benschop, Kimberley S.M., Van Leer-Buter, Coretta C., Meijer, Adam, Bakker, Dewi P., de Bie, Eva, Braakman, Hilde M.H., Brandsma, Rick, Niks, Erik H., Niermeijer, Jikke-Mien, Roelfsema, Vincent, Schoenmaker, Niels, Sie, Lilian T., Niesters, Hubert G., te Wierik, Margreet J.M., Jacobs, Bart C., and Brouwer, Oebele F.
Published: 2023
Full Text: View/download PDF

2. Impact of the COVID‐19 Pandemic on Influenza Circulation During the 2020/21 and 2021/22 Seasons, in Europe

Author: Sinnathamby, Mary A., Meslé, Margaux M. I., Mook, Piers, Pebody, Richard, Bino, Silvia, Hasibra, Iris, Bakunts, Nune, Abovyan, Romella, Khachtryan, Evgenia, Redlberger‐Fritz, Monika, Mursalova, Nazifa, Aliyeva, Firuza, Vysotskaya, Veronika, Shmialiova, Natallia, Karaban, Inna, Bossuyt, Nathalie, Barbezange, Cyril, Musa, Sanja, Vukmir, Nina Rodić, Ljubović, Amela Dedeić, Baštinac, Dijana, Vladimirov, Nadezhda, Korsun, Neli, Trifonova, Ivelina, Tabain, Irena, Petrović, Goranka, Karagiannis, Christos, Haralambous, Christos, Jirincova, Helena, Kyncl, Jan, Trebbien, Ramona, Vestergaard, Lasse Skafte, Sadikova, Olga, Eero, Irina, Metsoja, Eliisa, Ikonen, Niina, Lyytikäinen, Outi, Nohynek, Hanna, Fournier, Lucie, Guerrisi, Caroline, Valette, Martine, Machablishvili, Ani, Buda, Silke, Dürrwald, Ralf, Gioula, Georgia, Mary, Emmanouil, Mellou, Kassiani, Rózsa, Mónika, Molnár, Zsuzsanna, Armannsdottir, Brynja, Aspelund, Guðrún, O’Donnell, Joan, Domegan, Lisa, Connell, Jeff, Mandelboim, Michal, Glatman‐Freedman, Aharona, Puzelli, Simona, Palamara, Anna Teresa, Maraglino, Francesco, Smagulova, Smagulova Meiramgul Kanapiyanovna, Userbayev, Aidar Sharipkhanuly, Kalaveshi, Ariana, Jakupi, Xhevat, Gunga, Zana Kaçaniku, Otorbaeva, D. S, Abdyldaeva, S. Zh, Esengeldiev, G. M, Vasiļevska, Darja, Tomašūna, Kate Karolīna, Savicka, Oksana, Gargasiene, Greta, Muralyte, Svajune, Nguyen, Trung‐Nguyen, Mossong, Joel, Abdelrahman, Tamir T., Melillo, Tanya, Zahra, Graziella, Melillo, Jackie, Rakocevic, Bozidarka, Zekovic, Zeljka, Medenica, Sanja, de Lange, Marit, Meijer, Adam, Kochinski, Dragan, Boshevska, Golubinka, Paulsen, Trinehessevik, Bragstad, Karoline, Brydak, Lidia B., Hallmann, Ewelina, Szymański, Karol, Rodrigues, Ana Paula, Verdasca, Nuno, Guiomar, Raquel, Druc, Alina, Apostol, Mariana, Popescu, Rodica, Popovici, Odette, Lazar, Mihaela, Komissarov, Andrey B., Fadeev, Artem, Stolyarov, Kirill, Protić, Jelena, Avdičová, Mária, Mečochová, Adriana, Staroňová, Edita, Sočan, Maja, Prosenc, Katarina, Berginc, Nataša, Larrauri, Amparo, Mazagatos, Clara, Pozo, Francisco, Appelqvist, Emma, Carnahan, AnnaSara, Cabecinhas, Ana Rita Goncalves, Spedaliero, Tania, Jafarov, Navaruz, Safarova, Tamanno, Barotova, Barno, Kovalchuk, Tatyana, Altas, Ayse Basak, Avci, Emine, Ozdemir, Betul, Ovliyakulova, Gurbangul, Dykhanovska, Tetiana, Demchyshyna, Iryna, Koshako, Oksana, Watson, Conall, Zambon, Maria, Lakhani, Anissa, Shepherd, Samantha, Bradley, Declan T., Curran, Tanya, Moore, Catherine, Cottrell, Simon, Kudasheva, Lyudmila, Djemileva, Sultan, Pleshkov, Boris, Sinnathamby, Mary A., Meslé, Margaux M. I., Mook, Piers, Pebody, Richard, Bino, Silvia, Hasibra, Iris, Bakunts, Nune, Abovyan, Romella, Khachtryan, Evgenia, Redlberger‐Fritz, Monika, Mursalova, Nazifa, Aliyeva, Firuza, Vysotskaya, Veronika, Shmialiova, Natallia, Karaban, Inna, Bossuyt, Nathalie, Barbezange, Cyril, Musa, Sanja, Vukmir, Nina Rodić, Ljubović, Amela Dedeić, Baštinac, Dijana, Vladimirov, Nadezhda, Korsun, Neli, Trifonova, Ivelina, Tabain, Irena, Petrović, Goranka, Karagiannis, Christos, Haralambous, Christos, Jirincova, Helena, Kyncl, Jan, Trebbien, Ramona, Vestergaard, Lasse Skafte, Sadikova, Olga, Eero, Irina, Metsoja, Eliisa, Ikonen, Niina, Lyytikäinen, Outi, Nohynek, Hanna, Fournier, Lucie, Guerrisi, Caroline, Valette, Martine, Machablishvili, Ani, Buda, Silke, Dürrwald, Ralf, Gioula, Georgia, Mary, Emmanouil, Mellou, Kassiani, Rózsa, Mónika, Molnár, Zsuzsanna, Armannsdottir, Brynja, Aspelund, Guðrún, O’Donnell, Joan, Domegan, Lisa, Connell, Jeff, Mandelboim, Michal, Glatman‐Freedman, Aharona, Puzelli, Simona, Palamara, Anna Teresa, Maraglino, Francesco, Smagulova, Smagulova Meiramgul Kanapiyanovna, Userbayev, Aidar Sharipkhanuly, Kalaveshi, Ariana, Jakupi, Xhevat, Gunga, Zana Kaçaniku, Otorbaeva, D. S, Abdyldaeva, S. Zh, Esengeldiev, G. M, Vasiļevska, Darja, Tomašūna, Kate Karolīna, Savicka, Oksana, Gargasiene, Greta, Muralyte, Svajune, Nguyen, Trung‐Nguyen, Mossong, Joel, Abdelrahman, Tamir T., Melillo, Tanya, Zahra, Graziella, Melillo, Jackie, Rakocevic, Bozidarka, Zekovic, Zeljka, Medenica, Sanja, de Lange, Marit, Meijer, Adam, Kochinski, Dragan, Boshevska, Golubinka, Paulsen, Trinehessevik, Bragstad, Karoline, Brydak, Lidia B., Hallmann, Ewelina, Szymański, Karol, Rodrigues, Ana Paula, Verdasca, Nuno, Guiomar, Raquel, Druc, Alina, Apostol, Mariana, Popescu, Rodica, Popovici, Odette, Lazar, Mihaela, Komissarov, Andrey B., Fadeev, Artem, Stolyarov, Kirill, Protić, Jelena, Avdičová, Mária, Mečochová, Adriana, Staroňová, Edita, Sočan, Maja, Prosenc, Katarina, Berginc, Nataša, Larrauri, Amparo, Mazagatos, Clara, Pozo, Francisco, Appelqvist, Emma, Carnahan, AnnaSara, Cabecinhas, Ana Rita Goncalves, Spedaliero, Tania, Jafarov, Navaruz, Safarova, Tamanno, Barotova, Barno, Kovalchuk, Tatyana, Altas, Ayse Basak, Avci, Emine, Ozdemir, Betul, Ovliyakulova, Gurbangul, Dykhanovska, Tetiana, Demchyshyna, Iryna, Koshako, Oksana, Watson, Conall, Zambon, Maria, Lakhani, Anissa, Shepherd, Samantha, Bradley, Declan T., Curran, Tanya, Moore, Catherine, Cottrell, Simon, Kudasheva, Lyudmila, Djemileva, Sultan, and Pleshkov, Boris
Abstract: Background: The emergence of SARS‐CoV‐2 in late 2019 saw the implementation of public health and social measures (PHSM) by countries across Europe to reduce its transmission and impact on populations. Consequently, countries reported changes in influenza circulation and extensive disruptions to routine surveillance systems.MethodsWe describe the epidemiology of influenza in Europe between Weeks 40/2020 and 39/2022 compared to the 2016/17 to 2019/20 seasons, to assess the impact of the COVID‐19 pandemic and PHSM on surveillance systems and influenza circulation.ResultsLow detections of influenza were observed through primary care sentinel sources during seasonal influenza periods (Week 40 to 20); 56 (of 39,457 specimens tested; < 1% positivity) in 2020/21 and 7261 (of 64,153 specimens tested; 11% positivity) detections in 2021/22 were observed, compared to an average of 18,383 (of 50,544 specimens tested; 36% positivity) detections in 2016/17 to 2019/20. Similarly, 11 (of 19,989 specimens tested; < 1% positivity) and 1488 (of 23,636 specimens tested; 6% positivity) detections were reported through SARI surveillance sources in 2020/21 and 2021/22, respectively, compared to an average of 2850 (of 10,389 specimens tested; 27% positivity) detections in 2016/17 to 2019/20. However, the 2021/22 interseasonal period saw unusual increases in influenza detections across surveillance site types when PHSM were easing.ConclusionIn conclusion, findings suggest that the restriction and easing of PHSM measures were associated with variations in influenza detections. Our observations of out‐of‐season influenza activity highlight the importance of an integrated respiratory surveillance strategy to monitor circulating respiratory viruses throughout the year to inform optimal prevention and control strategies.
Published: 2024

3. Excess Deaths during Influenza and Coronavirus Disease and Infection-Fatality Rate for Severe Acute Respiratory Syndrome Coronavirus 2, the Netherlands

Author: van Asten, Liselotte, Harmsen, Carel N., Stoeldraijer, Lenny, Klinkenberg, Don, Teirlinck, Anne C., de Lange, Marit M.A., Meijer, Adam, van de Kassteele, Jan, van Gageldonk-Lafeber, Arianne B., van den Hof, Susan, and van der Hoek, Wim
Subjects: Epidemics -- Control -- Netherlands, Mortality -- Models -- Netherlands, Sentinel health events -- Technology application, Public health administration -- Technology application, Technology application, Health
Abstract: Influenza and coronavirus disease (COVID-19) are respiratory illnesses that show a high burden of disease. Comparison of their effect on death rates is critical in light of the discussion, especially [...]
Published: 2021
Full Text: View/download PDF

4. Cost-effectiveness of Screening Program for Chronic Q Fever, the Netherlands

Author: de Boer, Pieter T., de Lange, Marit M.A., Wielders, Cornelia C.H., Dijkstra, Frederika, van Roeden, Sonja E., Bleeker- Rovers, Chantal P., Oosterheert, Jan Jelrik, Schneeberger, Peter M., and van der Hoek, Wim
Subjects: Health screening -- Economic aspects, Epidemics -- Netherlands -- Economic aspects, Geospatial data -- Economic aspects, Cardiovascular diseases -- Economic aspects, Time, Databases, Health
Abstract: Chronic Q fever (CQF) is a potentially lethal condition that develops in 2% of Q fever (QF) patients (1). QF is caused by infection with Coxiella burnetii, a gram-negative bacterium [...]
Published: 2020
Full Text: View/download PDF

5. Should Acute Q-Fever Patients be Screened for Valvulopathy to Prevent Endocarditis?

Author: de Lange, Marit M. A., Gijsen, Laura E. V., Wielders, Cornelia C. H., van der Hoek, Wim, Scheepmaker, Arko, and Schneeberger, Peter M.
Published: 2018

6. Exposure to Coxiella burnetii and risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the Netherlands

Author: van Roeden, Sonja E, van Houwelingen, Fedor, Donkers, Chiel M J, Hogewoning, Sander J, de Lange, Marit M A, van der Hoek, Wim, Kampschreur, Linda M, Bonten, Marc J M, Hoepelman, Andy I M, Bleeker-Rovers, Chantal P, Wever, Peter C, and Oosterheert, Jan Jelrik
Published: 2018
Full Text: View/download PDF

7. High Coxiella burnetii Seroconversion Rate in Veterinary Students, the Netherlands, 2006-2010

Author: de Lange, Marit M.A., van der Hoek, Wim, Schneeberger, Peter M., Swart, Arno, Heederik, Dick J.J., Schimmer, Barbara, and Wouters, Inge M.
Subjects: Antigen-antibody reactions -- Health aspects, Q fever -- Risk factors, Medical students -- Statistics -- Health aspects, Rickettsiales infections -- Statistics -- Diagnosis, Health
Abstract: Qfever is caused by the bacteria Coxiella burnetii and can manifest as acute or chronic illness. Veterinarians who care for livestock are prone to C. burnetii infection (1,2). A high [...]
Published: 2020
Full Text: View/download PDF

8. Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination in a Cohort of Older Adults, Despite Effectively Reducing Laboratory-Confirmed Influenza Virus Infections

Author: van Beek, Josine, Veenhoven, Reinier H., Bruin, Jacob P., van Boxtel, Renée A. J., de Lange, Marit M. A., Meijer, Adam, Sanders, Elisabeth A. M., Rots, Nynke Y., and Luytjes, Willem
Published: 2017

9. Pediatric acute flaccid myelitis:Evaluation of diagnostic criteria and differentiation from other causes of acute flaccid paralysis

Author: Helfferich, Jelte, Neuteboom, Rinze F., de Lange, Marit M.A., Benschop, Kimberley S.M., Van Leer-Buter, Coretta C., Meijer, Adam, Bakker, Dewi P., de Bie, Eva, Braakman, Hilde M.H., Brandsma, Rick, Niks, Erik H., Niermeijer, Jikke Mien, Roelfsema, Vincent, Schoenmaker, Niels, Sie, Lilian T., Niesters, Hubert G., te Wierik, Margreet J.M., Jacobs, Bart C., Brouwer, Oebele F., Helfferich, Jelte, Neuteboom, Rinze F., de Lange, Marit M.A., Benschop, Kimberley S.M., Van Leer-Buter, Coretta C., Meijer, Adam, Bakker, Dewi P., de Bie, Eva, Braakman, Hilde M.H., Brandsma, Rick, Niks, Erik H., Niermeijer, Jikke Mien, Roelfsema, Vincent, Schoenmaker, Niels, Sie, Lilian T., Niesters, Hubert G., te Wierik, Margreet J.M., Jacobs, Bart C., and Brouwer, Oebele F.
Abstract: Background: Acute flaccid paralysis (AFP) is characterized by rapidly progressive limb weakness with low muscle tone. It has a broad differential diagnosis, which includes acute flaccid myelitis (AFM), a rare polio-like condition that mainly affects young children. Differentiation between AFM and other causes of AFP may be difficult, particularly at onset of disease. Here, we evaluate the diagnostic criteria for AFM and compare AFM to other causes of acute weakness in children, aiming to identify differentiating clinical and diagnostic features. Methods: The diagnostic criteria for AFM were applied to a cohort of children with acute onset of limb weakness. An initial classification based on positive diagnostic criteria was compared to the final classification, based on application of features suggestive for an alternative diagnosis and discussion with expert neurologists. Cases classified as definite, probable, or possible AFM or uncertain, were compared to cases with an alternative diagnosis. Results: Of 141 patients, seven out of nine patients initially classified as definite AFM, retained this label after further classification. For probable AFM, this was 3/11, for possible AFM 3/14 and for uncertain 11/43. Patients initially classified as probable or possible AFM were most commonly diagnosed with transverse myelitis (16/25). If the initial classification was uncertain, Guillain-Barré syndrome was the most common diagnosis (31/43). Clinical and diagnostic features not included in the diagnostic criteria, were often used for the final classification. Conclusion: The current diagnostic criteria for AFM usually perform well, but additional features are sometimes required to distinguish AFM from other conditions.
Published: 2023

10. Comparison of different collection methods for reported adverse events following pandemic and seasonal influenza vaccination

Author: Kemmeren, Jeanet, Honsbeek, Maaike, Dijkstra, Frederika, de Lange, Marit, van der Maas, Nicoline, Smallenburg, Ronald, Koppeschaar, Carl, and van der Hoek, Wim
Published: 2016
Full Text: View/download PDF

11. Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019

Author: Helfferich, Jelte, de Lange, Marit Ma, Benschop, Kimberley Sm, Jacobs, Bart C, Van Leer-Buter, Coretta C, Meijer, Adam, Bakker, Dewi P, de Bie, Eva, Braakman, Hilde Mh, Brandsma, Rick, Neuteboom, Rinze F, Niks, Erik H, Niermeijer, Jikke-Mien, Roelfsema, Vincent, Schoenmaker, Niels, Sie, Lilian T, Niesters, Hubert G, Brouwer, Oebele F, and Te Wierik, Margreet Jm
Subjects: Acute flaccid myelitis, enterovirus A71, children, surveillance, enterovirus D68, epidemiology, acute flaccid paralysis
Published: 2022

12. Epidemiology of acute flaccid myelitis in children in the Netherlands, 2014 to 2019

Author: Helfferich, Jelte, primary, de Lange, Marit MA, additional, Benschop, Kimberley SM, additional, Jacobs, Bart C, additional, Van Leer-Buter, Coretta C, additional, Meijer, Adam, additional, Bakker, Dewi P, additional, de Bie, Eva, additional, Braakman, Hilde MH, additional, Brandsma, Rick, additional, Neuteboom, Rinze F, additional, Niks, Erik H, additional, Niermeijer, Jikke-Mien, additional, Roelfsema, Vincent, additional, Schoenmaker, Niels, additional, Sie, Lilian T, additional, Niesters, Hubert G, additional, Brouwer, Oebele F, additional, and te Wierik, Margreet JM, additional
Published: 2022
Full Text: View/download PDF

13. Inference of age‐dependent case‐fatality ratios for seasonal influenza virus subtypes A(H3N2) and A(H1N1)pdm09 and B lineages using data from the Netherlands.

Author: McDonald, Scott A., Teirlinck, Anne C., Hooiveld, Mariette, van Asten, Liselotte, Meijer, Adam, de Lange, Marit, van Gageldonk‐Lafeber, Arianne B., and Wallinga, Jacco
Subjects: SEASONAL influenza, INFLUENZA viruses, INFLUENZA A virus, INFLUENZA B virus, GENERAL practitioners
Abstract: Background: Despite the known relatively high disease burden of influenza, data are lacking regarding a critical epidemiological indicator, the case‐fatality ratio. Our objective was to infer age‐group and influenza (sub)type specific values by combining modelled estimates of symptomatic incidence and influenza‐attributable mortality. Methods: The setting was the Netherlands, 2011/2012 through 2019/2020 seasons. Sentinel surveillance data from general practitioners and laboratory testing were synthesised to supply age‐group specific estimates of incidence of symptomatic infection, and ecological additive modelling was used to estimate influenza‐attributable deaths. These were combined in an Bayesian inferential framework to estimate case‐fatality ratios for influenza A(H3N2), A(H1N1)pdm09 and influenza B, per 5‐year age‐group. Results: Case‐fatality estimates were highest for influenza A(H3N2) followed by influenza B and then A(H1N1)pdm09 and were highest for the 85+ years age‐group, at 4.76% (95% credible interval [CrI]: 4.52–5.01%) for A(H3N2), followed by influenza B at 4.08% (95% CrI: 3.77–4.39%) and A(H1N1)pdm09 at 2.51% (95% CrI: 2.09–2.94%). For 55–59 through 85+ years, the case‐fatality risk was estimated to double with every 3.7 years of age. Conclusions: These estimated case‐fatality ratios, per influenza sub(type) and per age‐group, constitute valuable information for public health decision‐making, for assessing the retrospective and prospective value of preventative interventions such as vaccination and for health economic evaluations. [ABSTRACT FROM AUTHOR]
Published: 2023
Full Text: View/download PDF

14. Incidence and severity of SARS-CoV-2 infection in former Q fever patients as compared to the Dutch population, 2020-2021

Author: den Boogert, Elisabeth Maria, de Lange, Marit M A, Wielders, Cornelia C H, Rietveld, Ariene, Knol, Mirjam J, and van Gageldonk-Lafeber, Arianne B
Subjects: body regions, COVID-19, epidemiology, Q fever
Abstract: Surveillance data shows a geographical overlap between the early coronavirus disease 2019 (COVID-19) pandemic and the past Q fever epidemic (2007-2010) in the Netherlands. We investigated the relationship between past Q fever and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in 2020/2021, using a retrospective matched cohort study.In January 2021, former Q fever patients received a questionnaire on demographics, SARS-CoV-2 test results and related hospital/intensive care unit (ICU) admissions. SARS-CoV-2 incidence with 95% confidence intervals (CI) in former Q fever patients and standardised incidence ratios (SIR) to compare to the age-standardised SARS-CoV-2 incidence in the general regional population were calculated.Among 890 former Q fever patients (response rate: 68%), 66 had a PCR-confirmed SARS-CoV-2 infection. Of these, nine (14%) were hospitalised and two (3%) were admitted to ICU. From February to June 2020 the SARS-CoV-2 incidence was 1573/100 000 (95% CI 749-2397) in former Q fever patients and 695/100 000 in the general population (SIR 2.26; 95% CI 1.24-3.80). The incidence was not significantly higher from September 2020 to February 2021.We found no sufficient evidence for a difference in SARS-CoV-2 incidence or an increased severity in former Q fever patients vs. the general population during the period with widespread SARS-CoV-2 testing availability (September 2020-February 2021). This indicates that former Q fever patients do not have a higher risk of SARS-CoV-2 infection.
Published: 2022

15. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Author: Kissling, Esther, Hooiveld, Mariëtte, Martínez-Baz, Iván, Mazagatos, Clara, William, Naoma, Vilcu, Ana-Maria, Kooijman, Marjolein N, Ilić, Maja, Domegan, Lisa, Machado, Ausenda, de Lusignan, Simon, Lazar, Mihaela, Meijer, Adam, Brytting, Mia, Casado, Itziar, Larrauri, Amparo, Murray, Josephine-L K, Behillil, Sylvie, de Gier, Brechje, Mlinarić, Ivan, O'Donnell, Joan, Rodrigues, Ana Paula, Tsang, Ruby, Timnea, Olivia, de Lange, Marit, Riess, Maximilian, Castilla, Jesús, Pozo Sanchez, Francisco, Hamilton, Mark, Falchi, Alessandra, Knol, Mirjam J, Kurečić Filipović, Sanja, Dunford, Linda, Guiomar, Raquel, Cogdale, Jade, Cherciu, Carmen, Jansen, Tessa, Enkirch, Theresa, Basile, Luca, Connell, Jeff, Gomez, Verónica, Sandonis-Martin, Virginia, Bacci, Sabrina, Rose, Angela Mc, Pastore Celentano, Lucia, Valenciano, Marta, I-MOVE-COVID-19, ECDC primary care study teams, Conde-San Román, Patricia, Casas Flecha, Inmaculada, Oliva Dominguez, Jesus Angel, Delgado-Sanz, Concepcion, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Croatian Institute of Public Health [Zagreb] (CIPH), Health Service Executive [Dublin] (HSE), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), University of Oxford, Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Public Health Agency of Sweden, Instituto de Salud Carlos III [Madrid] (ISC), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Biologie des ARN et virus influenza - RNA Biology of Influenza Virus (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University College Dublin [Dublin] (UCD), UK Health Security Agency [London] (UKHSA), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), I-MOVE-COVID-19 and ECDC primary care study team Katica Čusek Adamić, Ivana Ferenčak, Bernard Kaić, Mirjana Lana Kosanović Ličina, Danijela Lakošeljac, Ivana Mihin Huskić, Diana Nonković, Nick Andrews, Jamie Lopez Bernal, Joanna Ellis, Heather Whitaker, Thierry Blanchon, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Lois O'Connor, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Rianne van Gageldonk-Lafeber, Susan J Hahné, Hester E de Melker, Ewout B Fanoy, Stijn Raven, Marit Middeldorp, Irina Kislaya, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Amélia Soeiro, Maria Elena Mihai, Iulia Bistriceanu, Alina Ivanciuc, Diana Dintoi, Catalina Pascu, Adrian Jidovu, Debbie Sigerson, Diogo Fp Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Inmaculada Casas Flecha, Ana Martínez Mateo, Daniel Castrillejo, Eva María Martínez Ochoa, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Cristina Burgui, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Pasi Penttinen, Christiana Carstairs, University of St Andrews. School of Medicine, Unión Europea. Comisión Europea. H2020, and European Centre for Disease Prevention and Control
Subjects: Test-negative design, RM, Delta variant, COVID-19 Vaccines, Epidemiology, [SDV]Life Sciences [q-bio], Multicentre study, Influenza, Human/prevention & control, MESH: Primary Health Care, Europe/epidemiology, MESH: Influenza Vaccines, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Influenza, Human, Humans, MESH: COVID-19, MESH: SARS-CoV-2, COVID-19/epidemiology, Vaccine effectiveness, QR355, MESH: Humans, Primary Health Care, vaccine effectiveness, SARS-CoV-2, MESH: Influenza, Human, Vaccination, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, MESH: Vaccination, NIS, multicentre study, RM Therapeutics. Pharmacology, Europe, Influenza Vaccines, MESH: COVID-19 Vaccines, SARS-COV-2, vaccine efffectiveness, MESH: Europe, QR355 Virology
Abstract: Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
Published: 2022

16. Contribution of Influenza Viruses, Other Respiratory Viruses and Viral Co-Infections to Influenza-like Illness in Older Adults

Author: Onderzoek, Child Health, Infection & Immunity, Cluster B, Kaaijk, Patricia, Swaans, Niels, Nicolaie, Alina M., Bruin, Jacob P., Van Boxtel, Renée A.J., De Lange, Marit M.A., Meijer, Adam, Sanders, Elisabeth A.M., van Houten, Marianne A., Rots, Nynke Y., Luytjes, Willem, van Beek, Josine, Onderzoek, Child Health, Infection & Immunity, Cluster B, Kaaijk, Patricia, Swaans, Niels, Nicolaie, Alina M., Bruin, Jacob P., Van Boxtel, Renée A.J., De Lange, Marit M.A., Meijer, Adam, Sanders, Elisabeth A.M., van Houten, Marianne A., Rots, Nynke Y., Luytjes, Willem, and van Beek, Josine
Published: 2022

17. Contribution of Influenza Viruses, Other Respiratory Viruses and Viral Co-Infections to Influenza-like Illness in Older Adults

Author: Kaaijk, Patricia, primary, Swaans, Niels, additional, Nicolaie, Alina M., additional, Bruin, Jacob P., additional, van Boxtel, Renée A. J., additional, de Lange, Marit M. A., additional, Meijer, Adam, additional, Sanders, Elisabeth A. M., additional, van Houten, Marianne A., additional, Rots, Nynke Y., additional, Luytjes, Willem, additional, and van Beek, Josine, additional
Published: 2022
Full Text: View/download PDF

18. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre study analysis by age-group, vaccine brand and time since vaccination, I-MOVE-COVID-19 and ECDC networks, July–August 2021

Author: Kissling, Esther, primary, Hooiveld, Mariëtte, additional, Martínez-Baz, Iván, additional, Mazagatos, Clara, additional, William, Naoma, additional, Vilcu, Ana-Maria, additional, Kooijman, Marjolein N., additional, Ilić, Maja, additional, Domegan, Lisa, additional, Machado, Ausenda, additional, de Lusignan, Simon, additional, Lazar, Mihaela, additional, Meijer, Adam, additional, Brytting, Mia, additional, Casado, Itziar, additional, Larrauri, Amparo, additional, Murray, Josephine-L K., additional, Behillil, Sylvie, additional, de Gier, Brechje, additional, Mlinarić, Ivan, additional, O'Donnell, Joan, additional, Rodrigues, Ana Paula, additional, Tsang, Ruby, additional, Timnea, Olivia, additional, de Lange, Marit, additional, Riess, Maximilian, additional, Castilla, Jesús, additional, Pozo, Francisco, additional, Hamilton, Mark, additional, Falchi, Alessandra, additional, Knol, Mirjam J., additional, Filipović, Sanja Kurečić, additional, Dunford, Linda, additional, Guiomar, Raquel, additional, Cogdale, Jade, additional, Cherciu, Carmen, additional, Jansen, Tessa, additional, Enkirch, Theresa, additional, Basile, Luca, additional, Connell, Jeff, additional, Gomez, Verónica, additional, Martín, Virginia Sandonis, additional, Bacci, Sabrina, additional, Rose, Angela MC, additional, Celentano, Lucia Pastore, additional, and Valenciano, Marta, additional
Published: 2021
Full Text: View/download PDF

19. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Author: Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020
Subjects: Infecções Respiratórias, Adult, Test-negative design, 2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, RM, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Primary health care, Primary care, 030204 cardiovascular system & hematology, Multicentre study, 03 medical and health sciences, Elderly, 0302 clinical medicine, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Medicine, Humans, 030212 general & internal medicine, Aged, Vaccine effectiveness, QR355, vaccine effectiveness, Primary Health Care, business.industry, SARS-CoV-2, Efetividade da vacina contra COVID-19, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, NIS, Estados de Saúde e de Doença, multicentre study, 3. Good health, RM Therapeutics. Pharmacology, Vaccination, Europe, Determinantes da Saúde e da Doença, business, QR355 Virology, Rapid Communication
Abstract: I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion
Published: 2021

20. Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020

Author: Kissling, Esther, Hooiveld, Mariëtte, Brytting, Mia, Vilcu, Ana-Maria, de Lange, Marit, Martínez-Baz, Iván, Sigerson, Debbie, Enkirch, Theresa, Belhillil, Sylvie, Meijer, Adam, Castilla, Jesus, William, Naoma, Carnahan, AnnaSara, Falchi, Alessandra, Hendriksen, Janneke, Casado, Itziar, Murray, Josie, Enouf, Vincent, Dijkstra, Frederika, Marques, Diogo F P, and Valenciano, Marta
Subjects: SARS-CoV-2, case-control study, test-negative design, COVID-19, influenza vaccination, multicentre study
Published: 2021

21. Cost-effectiveness of screening program for chronic q fever, the netherlands

Author: MS Infectieziekten, MS Interne Geneeskunde, Infection & Immunity, De Boer, Pieter T., De Lange, Marit M.A., Wielders, Cornelia C.H., Dijkstra, Frederika, Van Roeden, Sonja E., Bleeker-Rovers, Chantal P., Oosterheert, Jan Jelrik, Schneeberger, Peter M., Van Der Hoek, Wim, MS Infectieziekten, MS Interne Geneeskunde, Infection & Immunity, De Boer, Pieter T., De Lange, Marit M.A., Wielders, Cornelia C.H., Dijkstra, Frederika, Van Roeden, Sonja E., Bleeker-Rovers, Chantal P., Oosterheert, Jan Jelrik, Schneeberger, Peter M., and Van Der Hoek, Wim
Published: 2020

22. Absence of association between 2019‐20 influenza vaccination and COVID‐19: Results of the European I‐MOVE‐COVID‐19 primary care project, March‐August 2020

Author: Kissling, Esther, primary, Hooiveld, Mariëtte, additional, Brytting, Mia, additional, Vilcu, Ana‐Maria, additional, de Lange, Marit, additional, Martínez‐Baz, Iván, additional, Sigerson, Debbie, additional, Enkirch, Theresa, additional, Belhillil, Sylvie, additional, Meijer, Adam, additional, Castilla, Jesus, additional, William, Naoma, additional, Carnahan, AnnaSara, additional, Falchi, Alessandra, additional, Hendriksen, Janneke, additional, Casado, Itziar, additional, Murray, Josie, additional, Enouf, Vincent, additional, Dijkstra, Frederika, additional, Marques, Diogo F. P., additional, and Valenciano, Marta, additional
Published: 2021
Full Text: View/download PDF

23. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.

Author: Laniece Delaunay, Charlotte, Mazagatos, Clara, Martínez-Baz, Iván, Túri, Gergő, Goerlitz, Luise, Domegan, Lisa, Meijer, Adam, Rodrigues, Ana Paula, Sève, Noémie, Ilić, Maja, Latorre-Margalef, Neus, Lazar, Mihaela, Maurel, Marine, Melo, Aryse, Andreu Ivorra, Blanca, Casado, Itziar, Horváth, Judit Krisztina, Buda, Silke, Bennett, Charlene, and de Lange, Marit
Published: 2024
Full Text: View/download PDF

24. High Coxiella burnetii seroconversion rate in veterinary students, the Netherlands, 2006-2010

Author: de Lange, Marit M.A., primary, van der Hoek, Wim, additional, Schneeberger, Peter M., additional, Swart, Arno, additional, Heederik, Dick J. J., additional, Schimmer, Barbara, additional, and Wouters, Inge M., additional
Published: 2020
Full Text: View/download PDF

25. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort

Author: Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Gherasim, Alin, Brytting, Mia, Domegan, Lisa, Gomez, Veronica, Meijer, Adam, Lazar, Mihaela, Vucina, Vesna Visekruna, Duerrwald, Ralf, van der Werf, Sylvie, Larrauri, Amparo, Enkirch, Theresa, O'Donnell, Joan, Guiomar, Raquel, Hooiveld, Mariette, Petrovic, Goranka, Stoian, Elena, Penttinen, Pasi, Valenciano, Marta, Preuss, Ute, Tolksdorf, Kristin, Biere, Barbara, Smallfield, Maria, Wedde, Marianne, Falchi, Alessandra, Masse, Shirley, Villechenaud, Natacha, Souty, Cecile, Blanchon, Thierry, Launay, Titouan, Enouf, Vincent, Behillil, Sylvie, Lina, Bruno, Valette, Martine, Mazagatos, Clara, Casas, Inmaculada, Garcia Comas, Luis, Insua Marisquerena, Maria Esther, Carlos Galan, Juan, Castilla, Jesus, Garcia Cenoz, Manuel, Navascues, Ana, Quinones Rubio, Carmen, Ibanez Perez, Ana Carmen, Martinez Ochoa, Eva, Blasco, Miriam, Gimenez Duran, Jaume, Maria Vanrell, Juana, Reina, Jordi, Castrillejo, Daniel, Wiman, Asa, Hunt, Meadhbh, Joyce, Michael, Levis, Olga, Collins, Claire, Dunford, Linda, Bennett, Charlene, Moran, Joanne, Tuite, Grainne, Connell, Jeff, de Gascun, Cillian, Rodrigues, Ana Paula, Machado, Ausenda, Nunes, Baltazar, Kislaya, Irina, Costa, Ines, Conde, Patricia, Cristovao, Paula, Pechirra, Pedro, Borges, Vitor, Bagheri, Mariam, van den Brink, Sharon, Dijkstra, Frederika, Goderski, Gabriel, van der Hoek, Wim, de Lange, Marit, Marzec, Ton, Overduin, Pieter, Reukers, Daphne, Teirlinck, Anne, Wijsman, Lisa, Donker, Ge, Mihai, Maria Elena, Cherciu, Carmen Maria, Alexandrescu, Viorel, Kaic, Bernard, Filipovic, Sanja Kurecic, Novosel, Iva Pem, Makaric, Zvjezdana Lovric, Zajec, Martina, Drazenovic, Vladimir, Moren, Alain, I-MOVE Primary Care Study Team, EpiConcept [Paris], Instituto de Salud Carlos III [Madrid] (ISC), Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), and Netherlands Institute for Health Services Research [Utrecht] (NIVEL)
Subjects: vacunas de la gripe, Male, 0301 basic medicine, potencia vacunal, Epidemiology, [SDV]Life Sciences [q-bio], humanos, Gripe, adolescente, Hemagglutinin Glycoproteins, Influenza Virus, virus de la influenza A, 0302 clinical medicine, infecciones del tracto respiratorio, memoria inmunológica, vigilancia centinela, Determinantes de Saúde e Doença, Medicine, 030212 general & internal medicine, Respiratory Tract Infections, mediana edad, Vaccine effectiveness, anciano, birth cohorts, Birth cohorts, Estado de Saúde e Doença, resultado del tratamiento, Vaccination, Age Factors, Imprinting, adulto, Middle Aged, multicentre study, Europe, Treatment Outcome, Influenza A virus, Época 2018-2019, Influenza Vaccines, Population Surveillance, Female, Seasons, imprinting, influenza, Birth cohort, A(H3N2), Adult, Adolescent, Primary care, Multicentre study, vacunación, 03 medical and health sciences, vigilancia de la población, Virology, Influenza, Human, Humans, ddc:610, Vacina Antigripal, EuroEVA, Vaccine Potency, Aged, vaccine effectiveness, business.industry, Influenza A Virus, H3N2 Subtype, Research, Efetividade, Public Health, Environmental and Occupational Health, Influenza a, Influenza, estaciones (meteorología), 030104 developmental biology, influenza vaccination, test negative case control, vaccine effectiveness, 610 Medizin und Gesundheit, business, Immunologic Memory, Sentinel Surveillance, Demography
Abstract: Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32–54-year-olds (1964–86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results Influenza A(H3N2) VE among all ages was −1% (95% confidence interval (CI): −24 to 18) and 46% (95% CI: 8–68), −26% (95% CI: −66 to 4) and 20% (95% CI: −20 to 46) among 0–14, 15–64 and ≥ 65-year-olds, respectively. Among 15–64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: −34 to 50) and −74% (95% CI: −259 to 16), respectively. VE was −18% (95% CI: −140 to 41), −53% (95% CI: −131 to −2) and −12% (95% CI: −74 to 28) among 15–31-year-olds (1987–2003), 32–54-year-olds (1964–86) and 55–64-year-olds (1954–63), respectively. Discussion The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964–86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15–64-year-olds and the public health impact of the I-REV hypothesis warrant further study.
Published: 2019

26. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically-attended influenza: results of the European I-MOVE multicentre test-negative case-control study, 2011/12-2016/17

Author: Valenciano, Marta, Kissling, E, Larrauri, Amparo, Nunes, Baltasar, Pitigoi, Daniela, O Donnell, Joan, Reuss, Annicka, Horváth, Judit Krisztina, Paradowska-Stankiewicz, Iwona, Rizzo, Caterina, Falchi, Alessandra, Daviaud, Isabel, Brytting, Mia, Meijer, Adam, Kaic, Bernard, Gherasim, Alin, Machado, Ausenda, Ivanciuc, Alina, Domegan, Lisa, Schweiger, Brunhilde, Ferenczi, Annamária, Korczyńska, Monika, Bella, Antonino, Vilcu, Ana-Maria, Mosnier, Anne, Zakikhany, Katherina, Filipovićović, Sanja Kurečić, Johansen, Kari, Moren, Alain, and de Lange, Marit
Subjects: virus diseases
Abstract: Results of previous influenza vaccination effects on current season influenza vaccine effectiveness (VE) are inconsistent.
Published: 2018

27. Risk of chronic Q fever in patients with cardiac valvulopathy, seven years after a large epidemic in the Netherlands

Author: de Lange, Marit M. A., primary, Scheepmaker, Arko, additional, van der Hoek, Wim, additional, Leclercq, Monique, additional, and Schneeberger, Peter M., additional
Published: 2019
Full Text: View/download PDF

28. Exposure to Coxiella burnetii and risk of non-Hodgkin lymphoma : a retrospective population-based analysis in the Netherlands

Author: van Roeden, Sonja E., van Houwelingen, Fedor, Donkers, Chiel M.J., Hogewoning, Sander J., de Lange, Marit M.A., van der Hoek, Wim, Kampschreur, Linda M., Bonten, Marc J.M., Hoepelman, Andy I.M., Bleeker-Rovers, Chantal P., Wever, Peter C., Oosterheert, Jan Jelrik, van Roeden, Sonja E., van Houwelingen, Fedor, Donkers, Chiel M.J., Hogewoning, Sander J., de Lange, Marit M.A., van der Hoek, Wim, Kampschreur, Linda M., Bonten, Marc J.M., Hoepelman, Andy I.M., Bleeker-Rovers, Chantal P., Wever, Peter C., and Oosterheert, Jan Jelrik
Published: 2018

29. Exposure to Coxiella burnetii and risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the Netherlands

Author: MS Infectieziekten, Unit Opleiding Aios, MMB Serologie, Epi Infectieziekten, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Circulatory Health, MS Interne Geneeskunde, van Roeden, Sonja E., van Houwelingen, Fedor, Donkers, Chiel M.J., Hogewoning, Sander J., de Lange, Marit M.A., van der Hoek, Wim, Kampschreur, Linda M., Bonten, Marc J.M., Hoepelman, Andy I.M., Bleeker-Rovers, Chantal P., Wever, Peter C., Oosterheert, Jan Jelrik, MS Infectieziekten, Unit Opleiding Aios, MMB Serologie, Epi Infectieziekten, Infection & Immunity, JC onderzoeksprogramma Infectieziekten, Circulatory Health, MS Interne Geneeskunde, van Roeden, Sonja E., van Houwelingen, Fedor, Donkers, Chiel M.J., Hogewoning, Sander J., de Lange, Marit M.A., van der Hoek, Wim, Kampschreur, Linda M., Bonten, Marc J.M., Hoepelman, Andy I.M., Bleeker-Rovers, Chantal P., Wever, Peter C., and Oosterheert, Jan Jelrik
Published: 2018

30. Mortality surveillance in the Netherlands: winter 2015/2016 of moderate severity

Author: van Asten, Liselotte, de Lange, Marit, Teirlinck, Anne, Dijkstra, Frederika, Stoeldraijer, Lenny, Harmsen, Carel, and van der Hoek, Wim
Subjects: Excess mortality, European level, medicine.medical_specialty, business.industry, Mortality monitoring, Public health, Outbreak, Seasonality, medicine.disease, Mortality data, Pandemic, medicine, General Earth and Planetary Sciences, ISDS 2016 Conference Abstracts, influenza, business, General Environmental Science, Cause of death, Demography
Abstract: Objective Weekly numbers of deaths are monitored to increase the capacity to deal with both expected and unusual (disease) events such as pandemic influenza, other infections and non-infectious incidents. The monitoring information can potentially be used to detect, track and estimate the impact of an outbreak or incident on all-cause mortality. Introduction The mortality monitoring system (initiated in 2009 during the influenza A(H1N1) pandemic) is a collaboration between the Centre for Infectious Disease Control (CIb) and Statistics Netherlands. The system monitors nation-wide reported number of deaths (population size 2014: 16.8 million) from all causes, as cause of death information is not available real-time. Data is received from Statistics Netherlands by weekly emails. Methods Once a week the number of reported deaths is checked for excess above expected levels at 2 different time-lags: within 1 and 2 weeks after date of death (covering a median 43% and 96% of all deaths respectively). A weekly email bulletin reporting the findings is sent to the Infectious Disease Early Warning Unit (at CIb) and a summary of results is posted on the RIVM website (National Institute for Public Health and the Environment). Any known concurrent and possibly related events are also reported. When excess deaths coincide with hot temperatures, the bulletin is sent to the Heat Plan Team (also at RIVM). Data are also sent to EuroMOMO which monitors excess mortality at a European level. For the Dutch system baselines and prediction limits are calculated using a 5 year historical period (updated each July). A serfling-like algorithm based on regression analysis is used to produce baselines which includes cyclical seasonal trends (models based on historical data in which weeks with extreme underreporting have been removed. Also periods with high excess mortality in winter and summer were removed so as not to influence the baseline with previous outbreaks). Results Increased mortality occurred during the entire influenza epidemic and up to three weeks thereafter (weeks 1-14 of 2016), except for a drop in week 7 (figure1). Excess mortality was primarily observed in persons 75 or older. Additionally, in several weeks mortality was increased in 65-74 year olds, (weeknr 4-6; peaking in week 4 with 564 deaths, when 468 baseline deaths were predicted). Also, in week 4, mortality in the 25-34 year-old age group was significantly increased (25 deaths, while 14 were expected as baseline). Cumulative excess mortality was estimated at 3,900 deaths occurring during the 11 weeks of the 2015/2016 influenza epidemic and at 6,085 during the total winter season (44 weeks running from week 40 up to week 20). Conclusions In terms of number of deaths during the winter season (weeks 40-20) and during the influenza epidemic (weeks 1-11), the 2015/2016 season in the Netherlands was of moderate severity compared with the previous five years (and was of similar magnitude as the 2011/2012 winter). Notable was the short three-week time span with a higher peak in mortality in 65-74 year olds than has been observed in recent years. Although the influenza epidemic reached its peak in week 7, the mortality data showed a dip in week 7. The reason for the temporary decrease is unknown but there was a partial overlap with a public holiday.
Published: 2017

31. Reply to Million and Raoult

Author: de Lange, Marit M A, primary, Gijsen, Laura E V, additional, Wielders, Cornelia C H, additional, van der Hoek, Wim, additional, Scheepmaker, Arko, additional, and Schneeberger, Peter M, additional
Published: 2018
Full Text: View/download PDF

32. Mortality surveillance in the Netherlands: severity of winter 2016/2017

Author: Van Asten, Liselotte, primary, De Lange, Marit, additional, Teirlinck, Anne, additional, Stoeldraijer, Lenny, additional, Harmsen, Carel, additional, and Van der Hoek, Wim, additional
Published: 2018
Full Text: View/download PDF

33. Erratum to “Predominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe – Contribution of surveillance data from World Health Organization (WHO) European region to the WHO vaccine composition consultation for northern hemisphere 2017/18” [Vaccine 35 (2017) 4828–4835]

Author: Melidou, Angeliki, primary, Broberg, Eeva, additional, Adlhoch, Cornelia, additional, Snacken, René, additional, Penttinen, Pasi, additional, Pereyaslov, Dmitriy, additional, Brown, Caroline, additional, Redlberger-Fritz, Monika, additional, Popow-Kraupp, Therese, additional, Thomas, Isabelle, additional, Barbezange, Cyril, additional, Bossuyt, Nathalie, additional, Jirincova, Helena, additional, Nagy, Alexander, additional, Trebbien, Ramona, additional, Fischer, Thea K., additional, Ikonen, Niina, additional, Haveri, Anu, additional, Lyytikäinen, Outi, additional, Murtopuro, Satu, additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, van der Werf, Sylvie, additional, Falchi, Alessandra, additional, Valette, Martine, additional, Lina, Bruno, additional, Schweiger, Brunhilde, additional, Biere, Barbara, additional, Duwe, Susanne, additional, Wedde, Marianne, additional, Buda, Silke, additional, Mentis, Andreas, additional, Kossyvakis, Athanasios, additional, Pogka, Vasiliki, additional, Papa-Konidari, Anna, additional, Melidou, Angeliki, additional, Gioula, Georgia, additional, Exindari, Maria, additional, Dunford, Linda, additional, Connell, Jeff, additional, Tuite, Grainne, additional, Duffy, Margaret, additional, Moran, Joanne, additional, Hogg, Bridget, additional, Waters, Allison, additional, de Gascun, Cillian, additional, Domegan, Lisa, additional, O'Donnell, Joan, additional, Joyce, Michael, additional, Rita Castrucci, Maria, additional, Puzelli, Simona, additional, Rizzo, Caterina, additional, Bella, Antonino, additional, Maraglino, Francesco, additional, Otorbaeva, Dinagul, additional, Saparova, Gulbarchyn, additional, Zamjatina, Natalija, additional, Pakarna, Gatis, additional, Nikiforova, Raina, additional, Mossong, Joël, additional, Opp, Matthias, additional, Meijer, Adam, additional, Overduin, Pieter, additional, de Lange, Marit, additional, Teirlinck, Anne, additional, Rimmelzwaan, Guus, additional, van Beek, Ruud, additional, Koopmans, Marion, additional, Donker, Gé, additional, Hungnes, Olav, additional, Bragstad, Karoline, additional, Guiomar, Raquel, additional, Pechirra, Pedro, additional, Cristóvão, Paula, additional, Costa, Inês, additional, Conde, Patricia, additional, Paula Rodrigues, Ana, additional, Elena Ivanciuc, Alina, additional, Burtseva, Elena, additional, Kirillova, Elena, additional, Mukasheva, Evgeniya, additional, Tichá, Elena, additional, Prosenc, Katarina, additional, Berginc, Nataša, additional, Pozo, Francisco, additional, Casas, Inmaculada, additional, Larrauri, Amparo, additional, Oliva, Jesús, additional, Delgado, Concha, additional, Ortiz de Lejarazu Leonardo, Raúl, additional, Brytting, Mia, additional, Wiman, Åsa, additional, Cordey, Samuel, additional, Rita Goncalves, Ana, additional, Perisa, Damir, additional, Born, Rita, additional, Ellis, Joanna, additional, Galiano, Monica, additional, Thompson, Catherine, additional, Zambon, Maria, additional, Pebody, Richard, additional, Gunson, Rory, additional, Reynolds, Arlene, additional, McMenamin, Jim, additional, McCaughey, Conall, additional, and Kearns, Cathriona, additional
Published: 2018
Full Text: View/download PDF

34. Mortality surveillance in the Netherlands: winter 2015/2016 of moderate severity

Author: De Lange, Marit, primary, Teirlinck, Anne, additional, Dijkstra, Frederika, additional, Stoeldraijer, Lenny, additional, Harmsen, Carel, additional, and Van der Hoek, Wim, additional
Published: 2017
Full Text: View/download PDF

35. Influenza Vaccine Effectiveness in the Netherlands from 2003/2004 through 2013/2014: The Importance of Circulating Influenza Virus Types and Subtypes

Author: Darvishian, Maryam, primary, Dijkstra, Frederika, additional, van Doorn, Eva, additional, Bijlsma, Maarten J., additional, Donker, Gé A., additional, de Lange, Marit M. A., additional, Cadenau, Laura M., additional, Hak, Eelko, additional, and Meijer, Adam, additional
Published: 2017
Full Text: View/download PDF

36. European surveillance for enterovirus D68 during the emerging North-American outbreak in 2014

Author: Poelman, Randy, Schuffenecker, Isabelle, Van Leer-Buter, Coretta, Josset, Laurence, Niesters, Hubert G. M., Lina, Bruno, Popow-Kraupp, Theresia, Aberle, Stephan W., Fischer, Thea Kølsen, Midgley, Sofie, Christiansen, Claus Bohn, Waris, Matti, Österback, Riikka, Vuorinen, Tytti, Savolainen-Kopra, Carita, Latronico, Francesca, Blomqvist, Soile, Ikonen, Niina, Lappalainen, Maija, Jääskeläinen, Anne, Smura, Teemu, Pilorge, Léa, Legrand-Quillien, Marie-Christine, Payan, Christopher, Petitjean, Joëlle, Vabret, Astrid, Ribault, Mélanie, Mirand, Audrey, Peigue-Lafeuille, Hélène, Henquell, Cécile, Manoha, Catherine, Bour, Jean-Baptiste, Darniot, Magali, Le Goff, Jérôme, Mercier-Delarue, Séverine, Scieux, Catherine, Pillet, Sylvie, Pozzetto, Bruno, Lepiller, Quentin, Fafi-Kremer, Samira, Stoll-Keller, Françoise, Marque-Juillet, Stéphanie, Coutard, Aymeric, Amara, Marlène, Böttcher, Sindy, Diedrich, Sabine, Eis-Hübinger, Anna Maria, Aldabbagh, Souhaib, Reber, Ulrike, Panning, Marcus, Huzly, Daniela, Bierbaum, Sibylle, Liebert, Uwe G., Maier, Melanie, Carr, Michael J., Tuite, Gráinne, Guerra, Jorge Abboud, O'Gorman, Joanne, De Gascun, Cillian, Baldanti, Fausto, Piralla, Antonio, Esposito, Susanna, Principi, Nicola, Ruggiero, Luca, Opp, Matthias, Donker, Gé, Meijer, Adam, van der Avoort, Harrie, Benschop, Kimberley, de Lange, Marit, Niesters, Hubert, Borger, Renze, Scholvinck, Liesbeth, van der Reijden, Wil, Veenendaal, Dick, Claas, Eric C. J., Vossen, Ann C. T. M., Rahamat-Langendoen, Janette, Melchers, Willem J. G., Koopmans, Marion P. G., van der Eijk, Annemiek A., Pas, Suzan D., Kran, Anne-Marte Bakken, Bragstad, Karoline, Dudman, Susanne Gjeruldsen, Christensen, Andreas, Krokstad, Sidsel, Pancer, Katarzyna, Abramczuk, Edyta, Guiomar, Raquel, Pechirra, Pedro, Cristovão, Paula, Costa, Ines, Tecu, Cristina, Lupulescu, Emilia, Cherciu, Carmen, Goldstein, Emily, Bennett, Susan, Bradley-Stewart, Amanda, Gunson, Rory, Berginc, Natasa, Prosenc, Katarina, Campins, Magda, Gimferrer, Laura, Anton, Andres, López-Labrador, F. Xavier, Pérez, Laura Cano, Puig-Barberá, Joan, Cardona, Concepción Gimeno, Mochón, M Dolores Ocete, Buesa, Javier, Navarro, David, de Lejarazu Leonardo, R. Ortiz, Muñoz, Iván Sanz, Rojo, Silvia, Gozalo-Margüello, Mónica, Balbín, Jesús Agüero, Albert, Jan, Samuelson, Agneta, Östlund, Maria Rotzén, Dyrdak, Robert, Brytting, Mia, Hauzenberger, Elenor, Zakikhany, Katherina, Eriksson, Margareta, Moore, Catherine, Broberg, Eeva, Penttinen, Pasi, Mcculloch, Elaine, Di Lorenzo, Caterina, Wallace, Paul, Van Loon, Anton, Prifert, Christiane, Weißbrich, Benedikt, Adams, Ortwin, Berlin, Labor, Hofmann, Jörg, Schnitzler, Paus, Microbes in Health and Disease (MHD), Laboratoire de Biologie et de Pharmacologie Appliquée (LBPA), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), Virologie et pathologie humaine (VirPath), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Laboratoire Microorganismes : Génome et Environnement (LMGE), Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Virology, Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre National de la Recherche Scientifique (CNRS), Department of Virology, Medicum, and Viral Zoonosis Research Unit
Subjects: Male, Pediatrics, NETHERLANDS, CHILDREN, medicine.disease_cause, Disease Outbreaks, EMERGENCE, Respiratory infection, Epidemiology, Prospective Studies, Child, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Enterovirus D, Human, 318 Medical biotechnology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Middle Aged, 3. Good health, Europe, Geography, Infectious Diseases, INFECTIONS, Child, Preschool, Molecular epidemiology, Epidemiological Monitoring, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Female, Enterovirus D68, VP1 sequencing, Adult, medicine.medical_specialty, Adolescent, INHIBITION, Enterovirus D, ta3111, [SDV.MP.PRO]Life Sciences [q-bio]/Microbiology and Parasitology/Protistology, RESPIRATORY ILLNESS, Young Adult, SDG 3 - Good Health and Well-being, Virology, Enterovirus Infections, medicine, Humans, Disease burden, Aged, Retrospective Studies, Viral Structural Proteins, PEDIATRIC-PATIENTS, business.industry, Infant, Newborn, ta1182, Infant, Outbreak, Retrospective cohort study, Sequence Analysis, DNA, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Molecular Typing, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], VIRAL 2A PROTEASE, HUMAN RHINOVIRUS, North America, REPLICATION, Enterovirus, business
Abstract: M. Lappalainen, A. Jääskeläinen ja T. Smura ovat työryhmän ESCV-ECDC EV-D68 Study Grp jäseniä. Background: In August and September 2014, unexpected clusters of enterovirus-D68 (EV-D68) infections associated with severe respiratory disease emerged from North-America. In September, the European Centre for Disease Prevention and Control (ECDC) asked European countries to strengthen respiratory sample screening for enterovirus detection and typing in cases with severe respiratory presentations. Objectives: To provide a detailed picture of EV-D68 epidemiology in Europe by conducting a retrospective and prospective laboratory analysis of clinical specimens. Study design: An initiative supported by the European Society for Clinical Virology (ESCV) and ECDC was launched to screen for EV-D68 in respiratory specimens between July 1st and December 1st 2014 in Europe and to sequence the VP1 region of detected viruses for phylogenetic analytic purposes. Results: Forty-two institutes, representing 51 laboratories from 17 European countries, analyzed 17,248 specimens yielding 389 EV-D68 positive samples (2.26%) in 14 countries. The proportion of positive samples ranged between 0 and 25% per country. These infections resulted primarily in mild respiratory disease, mainly detected in young children presenting with wheezing and in immuno-compromised adults. The viruses detected in Europe are genetically very similar to those of the North-American epidemic and the majority (83%) could be assigned to clade B. Except for 3 acute flaccid paralysis (AFP) cases, one death and limited ICU admissions, no severe cases were reported. Conclusions: The European study showed that EV-D68 circulated in Europe during summer and fall of 2014 with a moderate disease burden and different pathogenic profile compared to the North-American epidemic. (C) 2015 The Authors. Published by Elsevier B.V.
Published: 2015

37. Long-Term Correlation between Influenza Vaccination Coverage and Incidence of Influenza-Like Illness in 14 European Countries

Author: Spruijt, Ineke T., primary, de Lange, Marit M. A., additional, Dijkstra, Frederika, additional, Donker, Gé A., additional, and van der Hoek, Wim, additional
Published: 2016
Full Text: View/download PDF

38. Erratum to “Predominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe – Contribution of surveillance data from World Health Organization (WHO) European region to the WHO vaccine composition consultation for northern hemisphere 2017/18” [Vaccine 35 (2017) 4828–4835]

Author: Adlhoch, Cornelia, Snacken, René, Penttinen, Pasi, Pereyaslov, Dmitriy, Brown, Caroline, Redlberger-Fritz, Monika, Popow-Kraupp, Therese, Thomas, Isabelle, Barbezange, Cyril, Bossuyt, Nathalie, Jirincova, Helena, Nagy, Alexander, Trebbien, Ramona, Fischer, Thea K., Ikonen, Niina, Haveri, Anu, Lyytikäinen, Outi, Murtopuro, Satu, Behillil, Sylvie, Enouf, Vincent, van der Werf, Sylvie, Falchi, Alessandra, Valette, Martine, Lina, Bruno, Schweiger, Brunhilde, Biere, Barbara, Duwe, Susanne, Wedde, Marianne, Buda, Silke, Mentis, Andreas, Kossyvakis, Athanasios, Pogka, Vasiliki, Papa-Konidari, Anna, Melidou, Angeliki, Gioula, Georgia, Exindari, Maria, Dunford, Linda, Connell, Jeff, Tuite, Grainne, Duffy, Margaret, Moran, Joanne, Hogg, Bridget, Waters, Allison, de Gascun, Cillian, Domegan, Lisa, O'Donnell, Joan, Joyce, Michael, Rita Castrucci, Maria, Puzelli, Simona, Rizzo, Caterina, Bella, Antonino, Maraglino, Francesco, Otorbaeva, Dinagul, Saparova, Gulbarchyn, Zamjatina, Natalija, Pakarna, Gatis, Nikiforova, Raina, Mossong, Joël, Opp, Matthias, Meijer, Adam, Overduin, Pieter, de Lange, Marit, Teirlinck, Anne, Rimmelzwaan, Guus, van Beek, Ruud, Koopmans, Marion, Donker, Gé, Hungnes, Olav, Bragstad, Karoline, Guiomar, Raquel, Pechirra, Pedro, Cristóvão, Paula, Costa, Inês, Conde, Patricia, Paula Rodrigues, Ana, Elena Ivanciuc, Alina, Burtseva, Elena, Kirillova, Elena, Mukasheva, Evgeniya, Tichá, Elena, Prosenc, Katarina, Berginc, Nataša, Pozo, Francisco, Casas, Inmaculada, Larrauri, Amparo, Oliva, Jesús, Delgado, Concha, Ortiz de Lejarazu Leonardo, Raúl, Brytting, Mia, Wiman, Åsa, Cordey, Samuel, Rita Goncalves, Ana, Perisa, Damir, Born, Rita, Ellis, Joanna, Galiano, Monica, Thompson, Catherine, Zambon, Maria, Pebody, Richard, Gunson, Rory, Reynolds, Arlene, McMenamin, Jim, McCaughey, Conall, Kearns, Cathriona, and Broberg, Eeva
Published: 2018
Full Text: View/download PDF

39. Een raadsel ontrafeld?: Ruslands verleden, heden en toekomst

Author: Kraft van Ermel, Nicolaas, Balt, Jolke, Benedictus, Rienk-Jan, van Koningsbrugge, Johannus, de Lange, Marit, and Smit, Gerrit-Jan
Published: 2013

40. Mortality Monitoring in the Netherlands

Author: Van Asten, Liselotte, primary, De Lange, Marit, additional, Harmsen, Carel, additional, Van den Wijngaard, Kees, additional, Kretzschmar, Mirjam, additional, and Van der Hoek, Wim, additional
Published: 2014
Full Text: View/download PDF

41. Exposure to Coxiella burnetiiand risk of non-Hodgkin lymphoma: a retrospective population-based analysis in the Netherlands

Author: van Roeden, Sonja E, van Houwelingen, Fedor, Donkers, Chiel M J, Hogewoning, Sander J, de Lange, Marit M A, van der Hoek, Wim, Kampschreur, Linda M, Bonten, Marc J M, Hoepelman, Andy I M, Bleeker-Rovers, Chantal P, Wever, Peter C, and Oosterheert, Jan Jelrik
Abstract: An association between Coxiella burnetiiand non-Hodgkin lymphoma has been suggested. After a large Q fever epidemic in the Netherlands (2007–10), we postulated that the incidence of non-Hodgkin lymphoma would be increased during and after the epidemic in areas with a high endemicity of Q fever compared with those with low endemicity.
Published: 2018
Full Text: View/download PDF

42. Comparison of five influenza surveillance systems during the 2009 pandemic and their association with media attention

Author: de Lange, Marit MA, primary, Meijer, Adam, additional, Friesema, Ingrid HM, additional, Donker, Gé A, additional, Koppeschaar, Carl E, additional, Hooiveld, Mariëtte, additional, Ruigrok, Nel, additional, and van der Hoek, Wim, additional
Published: 2013
Full Text: View/download PDF

43. Rapid Susceptibility Testing and Microcolony Analysis of Candida spp. Cultured and Imaged on Porous Aluminum Oxide

Author: Ingham, Colin J., primary, Boonstra, Sjoukje, additional, Levels, Suzanne, additional, de Lange, Marit, additional, Meis, Jacques F., additional, and Schneeberger, Peter M., additional
Published: 2012
Full Text: View/download PDF

44. Nationwide registry-based ecological analysis of Q fever incidence and pregnancy outcome during an outbreak in the Netherlands.

Author: de Lange, Marit M. A., Hukkelhoven, Chantal W. P. M., Munster, Janna M., Schneeberger, Peter M., and van der Hoek, Wim
Abstract: Objective: Whether areas affected by Q fever during a large outbreak (2008-2010) had higher rates of adverse pregnancy outcomes than areas not affected by Q fever. Design: Nationwide registry-based ecological study. Setting: Pregnant women in areas affected and not affected by Q fever in the Netherlands, 2003-2004 and 2008-2010. Participants: Index group (N=58 737): pregnant women in 307 areas with more than two Q fever notifications. Reference group (N=310 635): pregnant women in 921 areas without Q fever notifications. As a baseline, pregnant women in index and reference areas in the years 2003-2004 were also included in the reference group to estimate the effect of Q fever in 2008-2010, and not the already existing differences before the outbreak. Main outcome measures: Preterm delivery, small for gestational age, perinatal mortality. Results: In 2008-2010, there was no association between residing in a Q fever-affected area and both preterm delivery (adjusted OR 1.01 (95% CI 0.94 to 1.08)), and perinatal mortality (adjusted OR 0.87 (95% CI 0.72 to 1.05)). In contrast, we found a weak significant association between residing in a Q fever-affected area in 2008-2010 and small for gestational age (adjusted OR 1.06 (95% CI 1.01 to 1.12)), with a population-attributable fraction of 0.70% (95% CI 0.07% to 1.34%). We observed no dose-response relation for this outcome with increasing Q fever notifications, and we did not find a stronger association for women who were in their first trimester of pregnancy during the months of high human Q fever incidence. Conclusions: This study found a weak association between residing in a Q fever-affected area and the pregnancy outcome small for gestational age. Early detection of infection would require mass screening of pregnant women; this does not seem to be justified considering these results, and the uncertainties about its efficacy and the adverse effects of antibiotic treatment. [ABSTRACT FROM AUTHOR]
Published: 2015
Full Text: View/download PDF

45. The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years

Author: McDonald, Scott A., Lagerweij, Giske R., de Boer, Pieter, de Melker, Hester E., Pijnacker, Roan, Mughini Gras, Lapo, Kretzschmar, Mirjam E., den Hartog, Gerco, van Gageldonk-Lafeber, Arianne B., Hofhuis, Agnetha, Teirlinck, Anne, van Lier, Alies, Boudewijns, Bronke, de Dreu, Miek, Valk, Anne-Wil, Jongenotter, Femke, Verstraten, Carolien, Broekhaar, Gert, Willekens, Guido, Veldhuijzen, Irene, Polman, Jan, van de Kassteele, Jan, Alblas, Jeroen, van Heereveld, Janneke, Heijne, Janneke, Bulsink, Kirsten, Wielders, Lieke, van Asten, Liselotte, Jenniskens, Liz, Soetens, Loes, Mulder, Maarten, Schipper, Maarten, de Lange, Marit, Smorenburg, Naomi, Neppelenbroek, Nienke, van den Berg, Patrick, de Oliveira Bressane Lima, Priscila, van Gaalen, Rolina, Wijburg, Sara, de Bruijn, Shahabeh Abbas Zadeh Siméon, van Iersel, Senna, Andeweg, Stijn, Wierenga, Sjoerd, Lanooij, Susan, Keijser, Sylvia, Smit, Tara, Klinkenberg, Don, Backer, Jantien, McDonald, Scott, Maxwell, Amber, Niessen, Annabel, de Gier, Brechje, Berry, Danytza, van Wees, Daphne, van Meijeren, Dimphey, Vos, Eric R. A., Dijkstra, Frederika, Kemmeren, Jeanet, Ainslie, Kylie, Middeldorp, Marit, Kooijman, Marjolein, Knol, Mirjam, Faber, Timor, Hoek, Albert, Geubbels, Eveline, van Benthem, Birgit, de Melker, Hester, Wallinga, Jacco, Hahné, Susan, van den Hof, Susan, and van den f, Susan
Full Text: View/download PDF

46. Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively

Author: Ron Fouchier, Paulo Jorge Nogueira, Amparo Larrauri, Susanne Gjeruldsen Dudman, Sylvie Van der WERF, Simona Puzelli, Frederika Dijkstra, Anu Haveri, Bruno Lina, Guillaume Fournier, Cyril Barbezange, Lisa Domegan, Cornelia Adlhoch, Thea Kølsen Fischer, Francisco Pozo, VASILIKI POGKA, Sibylle Bernard-Stoecklin, Caterina Rizzo, Lidia Brydak, Ramona Trebbien, Inmaculada Casas, Maria Rita Castrucci, Richard Pebody, European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), Aristotle University of Thessaloniki, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), We thank the influenza surveillance team at World Health Organization Regional Office for Europe, Copenhagen, Demark, for their collaboration. We thank all EISN members and ERLI-Net laboratories for their tireless commitment in collecting and providing high-quality European influenza surveillance data. We are also grateful to the TESSy data managers for their support and ECDC staff for their critical review., Members of the European Influenza Surveillance Network WHO: Piers Mook, Tamara Meerhoff, Austria: Theresia Popow-Kraupp, Daniela Schmid, Belgium: Barbezange Cyril, Bossuyt Nathalie, Moreels Sarah, Thomas Isabelle, Van Casteren Viviane, Bulgaria: Korsun Neli, Croatia: Draženović Vladimir, Cyprus: Koliou Maria, Pieridou Despo, Czech Republic: Havlíčková Martina, Jiřincová Helena, Kynčl Jan, Denmark: Fischer Thea Kølsen, Krause Knudsen Lisbet, Trebbien Ramona, Estonia: Päll Kaie, Sadikova Olga, Finland: Haveri Anu, Ikonen Niina, Lyytikäinen Outi, Murtopuro Satu, France: Behillil Sylvie, Bernard-Stoecklin Sibylle, Blanchon Thierry, Campese Christine, Enouf Vincent, Lina Bruno, Turbelin Clement, Valette Martine, van der Werf Sylvie, Germany: Buda Silke, Dürrwald Ralf, Greece: Kalkouni Ourania, Mentis Andreas, Papa Anna, Pogka Vasiliki, Hungary: Jankovics István, Molnár Zsuzsanna, Rózsa Mónika, Iceland: Löve Arthur, Sigmundsdóttir Guðrún, Ireland: Connell Jeff, Domegan Lisa, Duffy Margaret, Dunford Linda, O’Donnell Joan, Italy: Bella Antonino, Rizzo Caterina, Simona Puzelli, Maria Rita Castrucci, Latvia: Nikiforova Raina, Pakarna Gatis, Zamjatina Natalija, Liechtenstein: Jamnicki Abegg Marina, Lithuania: Griškevičius Algirdas, Lipnickienė Vilnelė, Muralytė Svajūnė, Luxembourg: Fournier Guillaume, Nguyen Trung, Malta: Barbara Christopher, Maistre Melillo Jackie, Melillo Tanya, Zahra Graziella, The Netherlands: de Lange Marit, Dijkstra Frederika, Donker Ge, Fouchier Ron, Hooiveld Mariette, Marbus Sierk, Meijer Adam, Teirlinck Anne, Norway: Bragstad Karoline, Dudman Susanne Gjeruldsen, Hauge Siri Helene, Hungnes Olav, Tønnessen Ragnhild, Poland: Brydak Lidia, Cieślak Katarzyna, Zielinski Andrzej, Portugal: Figueiredo Augusto Gonçalo, Machado Jorge, Moreira Guiomar Raquel, Nogueira Paulo, Rebelo De Andrade Helena, Rodrigues Ana Paula, Romania: Ivanciuc Alina, Odette Popovici, Popescu Rodica, Slovakia: Staronová Edita, Mikas Ján, Slovenia: Berginc Nataša, Prosenc Katarina, Sočan Maja, Grilc Eva, Spain: Casas Inmaculada, Delgado Sanz Concha, Larrauri Amparo, Marcos María Angeles, Oliva Jesus, Ortiz De Lejarazu Leonardo Raul, Pozo Francisco, Vega Tomas, Sweden: Mia Brytting, AnnaSara Carnahan, and United Kingdom: Coyle Peter, Daniels Rodney Stuart, Gunson Rory, Kearns Cathriona, MacLean Alasdair, McCaughey Conall, McMenamin Jim, Moore Catherine, Nugent Christopher, Pebody Richard, Phin Nick, Potts Alison, Reynolds Arlene, Shaw Primrose Louise, Zambon Maria.
Subjects: 0301 basic medicine, Male, Epidemiology, [SDV]Life Sciences [q-bio], Gripe, severity, Severity of Illness Index, Disease Outbreaks, 0302 clinical medicine, Estados de Saúde, 030212 general & internal medicine, Child, intensive care, Aged, 80 and over, Surveillance, virus diseases, Middle Aged, Europe, Vigilância, Intensive Care Units, Geography, Child, Preschool, Population Surveillance, surveillance, Female, epidemiology, Seasons, Iinfluenza, influenza, Rapid Communication, Adult, medicine.medical_specialty, Surveillance data, Adolescent, 030106 microbiology, Virus, Severity, 03 medical and health sciences, Young Adult, Virology, Intensive care, Influenza, Human, medicine, Humans, Circulation (currency), Mortality, Aged, Influenza A Virus, H3N2 Subtype, Public Health, Environmental and Occupational Health, Infant, Newborn, Infant, Influenza a, mortality, Influenza B virus, Influenza Surveillance, Sentinel Surveillance, Demography
Abstract: Members of the European Influenza Surveillance Network: Portugal (Figueiredo Augusto Gonçalo, Machado Jorge, Moreira Guiomar Raquel, Nogueira Paulo, Rebelo de Andrade Helena, Rodrigues Ana Paula) The yearly influenza epidemics during each winter season vary in burden and severity. During the 2016/17 and 2017/18 seasons, all-cause excess mortality was observed during periods of high influenza virus circulation. Our aim is to describe and compare the pattern of influenza virus circulation and related disease severity by number of patients and fatal cases in intensive care units (ICUs) across European Union/European Economic Area (EU/EEA) countries for the seasons 2016/17 and 2017/18. As influenza circulation progressed from a west to east direction across Europe in 2017/18, a better understanding of the current epidemiological situation might help to prepare countries in the eastern part of the World Health Organization (WHO) European Region for high influenza activity and severity. info:eu-repo/semantics/publishedVersion
Published: 2019

47. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022.

Author: Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ilić M, Maurel M, Melo A, Sandonis Martín V, Trobajo-Sanmartín C, Enouf V, McKenna A, Pérez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, Túri G, Castilla J, Falchi A, Bennett C, Gallardo V, Dürrwald R, Eggink D, Guiomar R, Popescu R, Riess M, Horváth JK, Casado I, García MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, and Kissling E
Subjects: Humans, Adolescent, Aged, COVID-19 Vaccines, SARS-CoV-2, BNT162 Vaccine, Vaccine Efficacy, Europe epidemiology, Primary Health Care, COVID-19 epidemiology, COVID-19 prevention & control, Influenza, Human epidemiology, Influenza, Human prevention & control
Abstract: BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants.AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases.MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection.ResultsAmong adults, PS VE was 37% (95% CI: 24-47%) overall and 60% (95% CI: 44-72%), 43% (95% CI: 26-55%) and 29% (95% CI: 13-43%) < 90, 90-179 and ≥ 180 days post vaccination, respectively. Booster VE was 42% (95% CI: 32-51%) overall and 56% (95% CI: 47-64%), 22% (95% CI: 2-38%) and 3% (95% CI: -78% to 48%), respectively. Primary series VE was similar among adolescents. Restricting analyses to Comirnaty had little impact. Vaccine effectiveness was higher among older adults. There was no signal of bias due to correlation between COVID-19 and influenza vaccination. Confounding by previous infection was low, but sample size precluded definite assessment of effect modification.ConclusionPrimary series and booster VE against symptomatic infection with BA.1/BA.2 ranged from 37% to 42%, with similar waning post vaccination. Comprehensive data on previous SARS-CoV-2 infection would help disentangle vaccine- and infection-induced immunity.
Published: 2024
Full Text: View/download PDF

48. Incidence and severity of SARS-CoV-2 infection in former Q fever patients as compared to the Dutch population, 2020-2021.

Author: den Boogert EM, de Lange MMA, Wielders CCH, Rietveld A, Knol MJ, and van Gageldonk-Lafeber AB
Subjects: COVID-19 Testing, Cohort Studies, Humans, Incidence, Retrospective Studies, SARS-CoV-2, COVID-19 epidemiology, Q Fever epidemiology
Abstract: Surveillance data shows a geographical overlap between the early coronavirus disease 2019 (COVID-19) pandemic and the past Q fever epidemic (2007-2010) in the Netherlands. We investigated the relationship between past Q fever and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in 2020/2021, using a retrospective matched cohort study.In January 2021, former Q fever patients received a questionnaire on demographics, SARS-CoV-2 test results and related hospital/intensive care unit (ICU) admissions. SARS-CoV-2 incidence with 95% confidence intervals (CI) in former Q fever patients and standardised incidence ratios (SIR) to compare to the age-standardised SARS-CoV-2 incidence in the general regional population were calculated.Among 890 former Q fever patients (response rate: 68%), 66 had a PCR-confirmed SARS-CoV-2 infection. Of these, nine (14%) were hospitalised and two (3%) were admitted to ICU. From February to June 2020 the SARS-CoV-2 incidence was 1573/100 000 (95% CI 749-2397) in former Q fever patients and 695/100 000 in the general population (SIR 2.26; 95% CI 1.24-3.80). The incidence was not significantly higher from September 2020 to February 2021.We found no sufficient evidence for a difference in SARS-CoV-2 incidence or an increased severity in former Q fever patients vs. the general population during the period with widespread SARS-CoV-2 testing availability (September 2020-February 2021). This indicates that former Q fever patients do not have a higher risk of SARS-CoV-2 infection.
Published: 2022
Full Text: View/download PDF

49. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021.

Author: Kissling E, Hooiveld M, Martínez-Baz I, Mazagatos C, William N, Vilcu AM, Kooijman MN, Ilić M, Domegan L, Machado A, de Lusignan S, Lazar M, Meijer A, Brytting M, Casado I, Larrauri A, Murray JK, Behillil S, de Gier B, Mlinarić I, O'Donnell J, Rodrigues AP, Tsang R, Timnea O, de Lange M, Riess M, Castilla J, Pozo F, Hamilton M, Falchi A, Knol MJ, Kurečić Filipović S, Dunford L, Guiomar R, Cogdale J, Cherciu C, Jansen T, Enkirch T, Basile L, Connell J, Gomez V, Sandonis Martín V, Bacci S, Rose AM, Pastore Celentano L, and Valenciano M
Subjects: COVID-19 Vaccines, Europe epidemiology, Humans, Primary Health Care, SARS-CoV-2, Vaccination, COVID-19 epidemiology, COVID-19 prevention & control, Influenza Vaccines, Influenza, Human prevention & control
Abstract: IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.
Published: 2022
Full Text: View/download PDF

50. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021.

Author: Kissling E, Hooiveld M, Sandonis Martín V, Martínez-Baz I, William N, Vilcu AM, Mazagatos C, Domegan L, de Lusignan S, Meijer A, Machado A, Brytting M, Casado I, Murray JK, Belhillil S, Larrauri A, O'Donnell J, Tsang R, de Lange M, Rodrigues AP, Riess M, Castilla J, Hamilton M, Falchi A, Pozo F, Dunford L, Cogdale J, Jansen T, Guiomar R, Enkirch T, Burgui C, Sigerson D, Blanchon T, Martínez Ochoa EM, Connell J, Ellis J, van Gageldonk-Lafeber R, Kislaya I, Rose AM, and Valenciano M
Subjects: Adult, Aged, COVID-19 Vaccines, Europe, Humans, Primary Health Care, COVID-19, SARS-CoV-2
Abstract: We measured COVID-19 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection at primary care/outpatient level among adults ≥ 65 years old using a multicentre test-negative design in eight European countries. We included 592 SARS-CoV-2 cases and 4,372 test-negative controls in the main analysis. The VE was 62% (95% CI: 45-74) for one dose only and 89% (95% CI: 79-94) for complete vaccination. COVID-19 vaccines provide good protection against COVID-19 presentation at primary care/outpatient level, particularly among fully vaccinated individuals.
Published: 2021
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

110 results on '"de Lange, Marit"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources